When there are no randomised clinical trials directly comparing all relevant treatment options, an indirect treatment comparison via meta-analysis of the available clinical evidence is an acceptable alternative. However, meta-analyses may be very misleading if not adequately performed. Here, we propose and validate a simple and effective approach to meta-analysis for exploring the effectiveness of long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations in chronic obstructive pulmonary disease.14 articles with 20 329 patients (combinations n=9292; monocomponents n=11 037) were included in this study. LABA/LAMA combinations were always more effective than the monocomponents in terms of the improvement in trough forced expiratory volume in 1 s, transition dyspnoea index and St George's Respiratory Questionnaire scores after 3, 6 and 12 months of treatment. No significant publication bias was identified. Significant discrepancies with previous network meta-analyses have been found, with overall differences ranging from 26.7% to 43.3%.Results from previous network meta-analyses were misleading because no adequate attention was given to formulating the review question, specifying eligibility criteria, correctly identifying studies, collecting appropriate information and deciding what it would be pharmacologically relevant to analyse. The real gradient of effectiveness of LABA/LAMA fixed-dose combinations remains an unmet medical need; however, it can be investigated indirectly using a high-quality meta-analytic approach.

Calzetta, L., Rogliani, P., Ora, J., Puxeddu, E., Cazzola, M., & Matera, M.g. (2017). LABA/LAMA combination in copd: A meta-analysis on the duration of treatment. EUROPEAN RESPIRATORY REVIEW, 26(143), 160043 [10.1183/16000617.0043-2016].

LABA/LAMA combination in copd: A meta-analysis on the duration of treatment

CALZETTA , LUIGINO;ROGLIANI, PAOLA;PUXEDDU, ERMANNO;CAZZOLA, MARIO;
2017

Abstract

When there are no randomised clinical trials directly comparing all relevant treatment options, an indirect treatment comparison via meta-analysis of the available clinical evidence is an acceptable alternative. However, meta-analyses may be very misleading if not adequately performed. Here, we propose and validate a simple and effective approach to meta-analysis for exploring the effectiveness of long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations in chronic obstructive pulmonary disease.14 articles with 20 329 patients (combinations n=9292; monocomponents n=11 037) were included in this study. LABA/LAMA combinations were always more effective than the monocomponents in terms of the improvement in trough forced expiratory volume in 1 s, transition dyspnoea index and St George's Respiratory Questionnaire scores after 3, 6 and 12 months of treatment. No significant publication bias was identified. Significant discrepancies with previous network meta-analyses have been found, with overall differences ranging from 26.7% to 43.3%.Results from previous network meta-analyses were misleading because no adequate attention was given to formulating the review question, specifying eligibility criteria, correctly identifying studies, collecting appropriate information and deciding what it would be pharmacologically relevant to analyse. The real gradient of effectiveness of LABA/LAMA fixed-dose combinations remains an unmet medical need; however, it can be investigated indirectly using a high-quality meta-analytic approach.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/10 - Malattie dell'Apparato Respiratorio
English
Con Impact Factor ISI
Calzetta, L., Rogliani, P., Ora, J., Puxeddu, E., Cazzola, M., & Matera, M.g. (2017). LABA/LAMA combination in copd: A meta-analysis on the duration of treatment. EUROPEAN RESPIRATORY REVIEW, 26(143), 160043 [10.1183/16000617.0043-2016].
Calzetta, L; Rogliani, P; Ora, J; Puxeddu, E; Cazzola, M; Matera, M
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/171459
Citazioni
  • ???jsp.display-item.citation.pmc??? 21
  • Scopus 44
  • ???jsp.display-item.citation.isi??? 44
social impact